Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
N/A
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05733780Phase 2Unknown

To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M

Role: lead

NCT05096052Phase 3Unknown

PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19

Role: lead

NCT04512027Not ApplicableCompleted

Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.

Role: collaborator

All 3 trials loaded